Log inSign up
AAOIFI No. 21 screening

Is XFOR halal?

X4 Pharmaceuticals, Inc.

Not halal

X4 Pharmaceuticals, Inc. did not pass AAOIFI screening. The failed check is shown below.

Checked: 15 October 2026

Exchange

NASDAQ

Price

2.59

Day

-1.89%

Market cap

$253.8M

Industry

Biotechnology

Sector

Healthcare

What the company does

X4 Pharmaceuticals won approval in 2024 for Xolremdi (mavorixafor), a drug for the rare immune disorder WHIM, and is now testing it in chronic neutropenia. Revenue is just starting; it still relies mostly on investor funding.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $76.76M ÷ 36-month average market cap $186.66M = 41.1%

    41.1%

    Fail

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $207.97M ÷ 36-month average market cap $186.66M = 111.4%

    111.4%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    Interest income $4.58M ÷ annual revenue $35.11M (2025) = 13.0%

    13.0%

    Fail

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $253.82M.

For information (AAOIFI 3/1 note): cash + receivables are 83.0% of total assets (2026-06-30). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyXFOR's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →